

Short-Term Risk of Serious Fall Injuries in Older Adults Initiating and Intensifying Treatment With Antihypertensive Medication

Daichi Shimbo, MD; C. Barrett Bowling, MD, MSPH; Emily B. Levitan, ScD; Luqin Deng, PhD; John J. Sim, MD; Lei Huang, MSPH; Kristi Reynolds, PhD, MPH; Paul Muntner, PhD

Background—Antihypertensive medication use has been associated with an increased risk of falls in some but not all studies. Few data are available on the short-term risk of falls after antihypertensive medication initiation and intensification.

Methods and Results—We examined the association between initiating and intensifying antihypertensive medication and serious fall injuries in a case-crossover study of 90 127 Medicare beneficiaries who were ≥ 65 years old and had a serious fall injury between July 1, 2007, and December 31, 2012, based on emergency department and inpatient claims. Antihypertensive medication initiation was defined by a prescription fill with no fills in the previous year. Intensification was defined by the addition of a new antihypertensive class, and separately, titration by the addition of a new class or increase in dosage of a current class. Exposures were ascertained for the 15 days before the fall (case period) and six 15-day earlier periods (control periods). Overall, 272, 1508, and 3113 Medicare beneficiaries initiated, added a new class of antihypertensive medication or titrated therapy within 15 days of their serious fall injury. The odds for a serious fall injury was increased during the 15 days after antihypertensive medication initiation (odds ratio, 1.36 [95% confidence interval, 1.19–1.55]), adding a new class (odds ratio, 1.16 [95% confidence interval, 1.10–1.23]), and titration [odds ratio, 1.13 [95% confidence interval, 1.08–1.18]]. These associations were attenuated beyond 15 days.

Conclusions—Antihypertensive medication initiation and intensification was associated with a short-term, but not long-term, increased risk of serious fall injuries among older adults. (*Circ Cardiovasc Qual Outcomes*. 2016;9:222–229. DOI: 10.1161/CIRCOUTCOMES.115.002524.)

Key Words: accidental falls ■ aged ■ antihypertensive agents ■ geriatrics

The benefit of antihypertensive medication on cardiovascular disease risk reduction has been demonstrated among older adults in randomized controlled trials.^{1–3} However, there may be unintended harm associated with antihypertensive medication use in older adults.^{4–7} Older adults are susceptible to adverse side effects associated with antihypertensive medication use, including postural hypotension, balance and gait impairment, dizziness, and electrolyte disturbances,^{8–10} which may increase the risk of serious fall injuries. Clinicians often weigh the cardiovascular disease risk-reduction benefits of antihypertensive medications against their potential for inducing fall injuries among older adults.

Some, but not all, studies suggest that antihypertensive medication use in older adults is associated with an increased risk for falls or injuries related to falls including fractures.^{4–7,11,12} Because most studies have examined prevalent users of antihypertensive medication, the relevance of these findings to clinical decision making on antihypertensive medication initiation or intensification is limited. Also, few data are available on the short-term

versus long-term risk for falls after initiation or intensification of antihypertensive medication.⁷ Determining whether antihypertensive medication initiation or intensification is associated with an increased risk for serious fall injuries and identifying a hazard period associated with increased risk have important implications, given the large number of older adults initiating and titrating antihypertensive medication¹³ and the availability of preventive strategies to reduce falls risk.¹⁴ We determined whether antihypertensive medication initiation is associated with a short-term increased risk for a serious fall injury among older US adults and whether the risk for a serious fall injury is similarly increased after antihypertensive medication intensification. We also examined the long-term fall injury risk after antihypertensive medication initiation and intensification.

Methods

We conducted 2 types of analyses using a national 5% random sample of Medicare beneficiaries from 2006 through 2012. The first analysis

Received November 27, 2015; accepted April 7, 2016.

From the Department of Medicine, Columbia University Medical Center, New York, NY (D.S.); Department of Veterans Affairs, Birmingham/Atlanta Geriatric Research, Education, and Clinical Center, Decatur, GA (C.B.B.); Emory University, Atlanta, GA (C.B.B.); Department of Epidemiology (E.B.L.), Department of Epidemiology (L.D.), Department of Epidemiology (L.H.), and Department of Epidemiology (P.M.), University of Alabama at Birmingham; Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA (J.J.S.); and Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA (K.R.).

The Data Supplement is available with this article at <http://circoutcomes.ahajournals.org/lookup/suppl/doi:10.1161/CIRCOUTCOMES.115.002524/-/DC1>.

Correspondence to Daichi Shimbo, MD, Columbia University Medical Center, 622 West 168th St, PH 9-310, New York, NY 10032. E-mail ds2231@cumc.columbia.edu

© 2016 American Heart Association, Inc.

Circ Cardiovasc Qual Outcomes is available at <http://circoutcomes.ahajournals.org>

DOI: 10.1161/CIRCOUTCOMES.115.002524

WHAT IS KNOWN

- In older adults, antihypertensive medication use has been associated with an increased risk of falls in some but not all studies.
- Few data are available on the short-term versus long-term risk for falls after initiation or intensification of antihypertensive medication in older adults.

WHAT THE STUDY ADDS

- Using Medicare claims from 2007 through 2012, we found that although the risk of a serious fall injury was low, there was a short-term increased risk of a serious fall injury within a 15-day period after initiation or intensification of antihypertensive medication.
- In contrast, the association between antihypertensive medication initiation or intensification and a serious fall injury was attenuated beyond 15 days.
- The results of this study suggest that antihypertensive medication initiation and intensification was associated with a short-term, but not long-term, increased risk of serious fall injuries among older adults.

was a retrospective cohort study, which was used to estimate the absolute risk for serious fall injuries among beneficiaries initiating and adding a new antihypertensive medication class or titrating antihypertensive medication. The second analysis was a case-crossover study of Medicare beneficiaries who experienced a serious fall injury. The case-crossover study was used to determine whether initiating and adding a new class or titrating antihypertensive medication were associated with an increased risk for serious fall injuries. Data used for the current analyses include claims from Medicare fee-for-service parts A (inpatient), B (outpatient), and D (prescription drug). Institutional review boards at the University of Alabama at Birmingham and the Center for Medicare and Medicaid Services approved this analysis.

Retrospective Cohort Study

Medicare beneficiaries who initiated antihypertensive medication between January 1, 2007, and December 31, 2011, were included in the retrospective cohort used to estimate the absolute risk for serious fall injuries in the 15 days after initiating and adding a new class and titration of treatment (Figure I in the Data Supplement). Initiation was defined by a Medicare Part D claim for antihypertensive medication with 365 continuous days of Medicare fee-for-service coverage (parts A, B, and D but not C) before the fill with no claims for antihypertensive medication. Medicare beneficiaries enrolled in a managed care program (part C) during this time period were not included because this is a capitated program and claims for these individuals are not complete. The date of the antihypertensive medication fill is provided with the claim. All medication classes filled within the 7 days after the date of initiation were included as part of the initiation regimen.¹⁵ We restricted the sample to beneficiaries with hypertension, defined by 1 or more outpatient physician evaluation and management claims with *International Classification of Diseases*, Ninth Revision diagnoses of 401.x (malignant, benign, or unspecified essential hypertension) during the 365 days before each beneficiary's first fill. We included Medicare beneficiaries with age ≥ 65 years old and < 110 years old at the start of the look-back period (365 days before the first antihypertensive medication fill) and having continuous residence in the United States during the look-back period to provide information for the general population of older US adults. Adding a new class of antihypertensive medication was defined by a Medicare part D claim for

a class of antihypertensive medication other than those filled on initiation. Titration was defined by adding a new class of antihypertensive medication or an increase in the dosage of the medication class filled on initiation. Adding a new antihypertensive medication class and titration were studied in the 365 days after initiation. Therefore, for these analyses, follow-up occurred through December 31, 2012.

Case-Crossover Study

The case-crossover study design is useful for investigating the transient effect of an exposure.^{16–18} Using this study design, only individuals who experience an outcome are analyzed, and each case serves as their own control. Medicare beneficiaries who experienced a serious fall injury event between July 1, 2007, and December 31, 2012, formed the base population for these analyses (Figure II in the Data Supplement). We used *International Classification of Diseases*, Ninth Edition, Clinical Modification and current procedure terminology codes to identify these events. Serious fall injuries were defined as emergency department and inpatient claims with a fall-related E code (8800–8889) and an injury code for nonpathological skull, facial, cervical, clavicle, humeral, forearm, pelvic, hip, fibula, tibia, or ankle fractures (80000–80619, 8070–8072, 8080–8089, 81000–81419, 8180–8251, or 8270–8291), brain injury (85200–85239), or dislocation of the hip, knee, shoulder, or jaw (8300–8321, 83500–83513, or 83630–83660).⁶ In the absence of a fall-related E code, an emergency department or inpatient claim with any of these codes was considered a serious fall injury as long as there was no motor vehicle accident E code (8100–8199).⁶ We required all beneficiaries to have at least 560 days of continuous Medicare fee-for-service coverage preceding the date of their serious fall injury. As described below, the 560-day interval includes the 195-day period (days 0–194) between the index date and the start of the earliest control period, and a 365-day period (days 195–559) before the earliest control period, which was used for assessing antihypertensive medication use and clinical characteristics. We restricted the population to Medicare beneficiaries with age ≥ 65 years old and < 110 years old 560 days before their fall injury and having continuous residence in the United States during the 560 days before their fall injury. For each beneficiary, we included the first occurrence of a serious fall injury meeting the above criteria. The date of the serious fall injury diagnosis was assigned as the index date.

The primary exposure was the initiation of antihypertensive medication. The case period was defined as the 15 days before and including the index date (days 0–14) and we selected six 15-day control periods (30–44, 60–74, 90–104, 120–134, 150–164, and 180–194 days before the index date). A schematic representation of this study design is presented in the Figure. For the case period and each control period, initiation of antihypertensive medication was defined by a claim in Medicare Part D for an angiotensin-converting enzyme inhibitor, aldosterone antagonist, angiotensin receptor blocker, α -blocker, β -blocker, calcium channel blocker, central acting agent, diuretic (thiazide-type, loop, or potassium sparing), renin inhibitor, or vasodilator with no claims for any of these medication classes during the 365 days before the first antihypertensive medication fill. These drugs were identified using National Drug Codes.

The risk for serious fall injuries associated with 2 secondary exposures representing antihypertensive medication intensification was examined: (1) addition of a new class of antihypertensive medication, and alternatively (2) antihypertensive medication titration. Addition of a new class of antihypertensive medication was defined as a fill for a class of antihypertensive medication within the case period or, separately, the control periods with no fills for that drug class during the preceding 365 days. Medication titration was defined as the addition of a new class of antihypertensive medication or an increase in the dosage of a medication class during the case or control periods.

Characteristics of Medicare Beneficiaries

Age, race/ethnicity, sex, region of residence, and calendar month of the fall were obtained from the Medicare beneficiary summary file. Using previously published algorithms,^{19–25} we identified a history of diabetes mellitus, coronary heart disease, heart failure, stroke,




Figure. Schematic representation of the case-crossover study design. For the case and each 15-day control period, separately, the initiation of antihypertensive medication was defined as a fill within the time period, with no antihypertensive medication fills during the 365 days before the first antihypertensive medication fill.

chronic kidney disease, syncope, osteoporosis, depression, or dementia. In addition, based on part D claims and National Drug Codes, the number of different generic medications, besides antihypertensive medications, that each beneficiary filled was determined. The Charlson score, a measure of overall comorbidity, was calculated.²⁶ In addition, a skilled nursing facility stay and any hospitalizations was identified in Medicare claims. These characteristics were identified at the time of initiation of antihypertensive medication for the retrospective cohort study and on the 365 days before the index date for the case-crossover study.

Statistical Analysis

For the retrospective cohort study, we calculated the percentage of Medicare beneficiaries experiencing a serious fall injury within 15 days after antihypertensive medication initiation. Among Medicare beneficiaries who initiated antihypertensive medication, characteristics at the time of initiation were calculated for those who experienced and did not experience a serious fall injury within 15 days. We then calculated the percentage of Medicare beneficiaries experiencing a serious fall injury within 15 days after adding a new antihypertensive medication class and medication titration.

For the case-crossover study, the characteristics of all Medicare beneficiaries who experienced a serious fall injury and those who experienced a serious fall injury within 15 days after initiation of antihypertensive medication were calculated. The distribution of classes of antihypertensive medication that were initiated in the 15-day case period and the 6 control periods were calculated for the overall sample and among Medicare beneficiaries with 1 or more diagnoses of hypertension. Because some drugs, classified as antihypertensive medication, may be prescribed for indications other than hypertension, sensitivity analyses were conducted in which the definitions of initiation, addition of a new antihypertensive medication class, and antihypertensive medication titration also required having 1 or more diagnoses of hypertension (*International Classification of Diseases*, Ninth Revision diagnoses of 401.xx) in the 365 days before the case or control period. Furthermore, because being hospitalized could result in an increased risk for falls and may be associated with initiation of antihypertensive medication, sensitivity analyses were conducted after excluding beneficiaries who were hospitalized in the 365 days before their serious fall injury. The odds ratio and 95% confidence interval (95% CI) for a serious fall injury associated with initiation of antihypertensive medication in the case period (0–14 days before the fall) were calculated using conditional logistic regression accounting for each beneficiary having 6 control periods (Table 1). Analyses were repeated using 1 (60–74 days before the fall) instead of 6 control periods. Cumulative mortality through 90 days after having a serious fall injury was determined. To assess the longer-term effects of initiating antihypertensive medication on risk for serious fall injuries, we calculated odds ratios (95% CI) using 3 alternate case and multiple control periods for each case period before the index date (ie, date of the serious fall injury; Table 1). Analyses were also repeated using 1 control period for each of the 3 case periods.

In exploratory analyses, odds ratios (95% CI) for a serious fall injury were also calculated within prespecified subgroups defined by demographics and the presence of medical comorbidities, which are associated with an increased risk of falls.^{27,28} Some studies have suggested that specific classes of antihypertensive medication are associated with a higher risk of falls or fractures.^{4,29} Furthermore, the majority of older US adults on antihypertensive medication are

taking 2 or more classes.⁶ Therefore, prespecified analyses were also conducted for subgroups defined by antihypertensive medication class and also the number of antihypertensive medication classes. Differences across subgroups were calculated using multiplicative interaction terms.

The case-crossover analyses were repeated to assess the association between adding a new class of antihypertensive medication and antihypertensive medication titration and the odds ratios for serious fall injuries. Analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC).

Results

Risk for Serious Fall Injuries in the Retrospective Cohort Study

Between January 1, 2007, and December 31, 2011, 65 210 Medicare beneficiaries who met the inclusion criteria initiated antihypertensive medication. Of this population, 186 (0.29%) Medicare beneficiaries had a serious fall injury within 15 days after treatment initiation. Beneficiaries who

Table 1. Case and Control Periods Used in Assessing the Odds Ratio for a Serious Fall Injury Associated With Initiation, Adding a New Drug Class, and Antihypertensive Medication Titration

Case Period	Control Periods (Primary Analyses)	Control Period (Secondary Analyses)
Analysis of short-term risk for serious fall injuries		
0–14 d	Six control periods, d 30–44 60–74 90–104 120–134 150–164 180–194	One control period, d 60–74
Analysis of long-term risk for serious fall injuries		
30–44 d	Five control periods, d 60–74 90–104 120–134 150–164 180–194	One control period, d 90–104
60–74 d	Four control periods 90–104 days 120–134 days 150–164 days 180–194 days	One control period, d 120–134
90–104 d	Three control periods, d 120–134 150–164 180–194	One control period 150–164 days

Table 2. Characteristics of Medicare Beneficiaries Experiencing a Serious Fall Injury Between July 1, 2007, and December 31, 2012, Overall and Within 15 days After Initiation of Antihypertensive Medication

Characteristic	All Beneficiaries (n=90 127)	Beneficiaries Who Initiated Antihypertensive Medication in Case Period (n=272)
Age on fall date		
<75 y	23 392 (26.0)	84 (30.9)
75–84 y	35 209 (39.1)	94 (34.6)
≥85 y	31 526 (35.0)	94 (34.6)
Male sex	21 499 (23.9)	77 (28.3)
Race/ethnicity		
White	80 567 (89.4)	244 (89.7)
Black	4341 (4.8)	12 (4.4)
Other	5219 (5.8)	16 (5.9)
Region		
Northeast	17 999 (20.0)	47 (17.3)
Midwest	22 968 (25.5)	69 (25.4)
South	34 673 (38.5)	110 (40.4)
West	14 487 (16.1)	46 (16.9)
Calendar month of fall		
January	7190 (8.0)	22 (8.1)
February	6538 (7.3)	23 (8.5)
March	6854 (7.6)	15 (5.5)
April	6721 (7.5)	24 (8.8)
May	6860 (7.6)	19 (7.0)
June	6737 (7.5)	21 (7.7)
July	7560 (8.4)	27 (9.9)
August	7966 (8.8)	21 (7.7)
September	7964 (8.8)	23 (8.5)
October	8237 (9.1)	23 (8.5)
November	8212 (9.1)	24 (8.8)
December	9288 (10.3)	30 (11.0)
History of diabetes mellitus	24 027 (26.7)	54 (19.9)
History of CHD	24 028 (26.7)	66 (24.3)
History of heart failure	14 231 (15.8)	36 (13.2)
History of stroke	2365 (2.6)	12 (4.4)
History of CKD	18 413 (20.4)	47 (17.3)
History of syncope	9542 (10.6)	33 (12.1)
History of osteoporosis	18 591 (20.6)	61 (22.4)
History of depression	17 515 (19.4)	70 (25.7)
History of dementia	17 905 (19.9)	68 (25.0)
Number of medication classes		

(Continued)

Table 2. Continued

Characteristic	All Beneficiaries (n=90 127)	Beneficiaries Who Initiated Antihypertensive Medication in Case Period (n=272)
0–5	18 085 (20.1)	75 (27.6)
6–10	28 888 (32.1)	90 (33.1)
>10	43 154 (47.9)	107 (39.3)
Charlson comorbidity index		
0	65 840 (73.1)	167 (61.4)
1–3	11 945 (13.3)	61 (22.4)
≥4	12 342 (13.7)	44 (16.2)
Any hospitalization in the previous year	29 916 (33.2)	126 (46.3)
Skilled nursing facility stay in the previous year	11 307 (12.5)	54 (19.9)

Data are expressed as number (percentage).
CHD indicates coronary heart disease; and CKD, chronic kidney disease.

initiated antihypertensive medication and had a serious fall injury within 15 days were older; less likely to be male; more likely to have a history of coronary heart disease, heart failure, stroke, syncope, osteoporosis, depression, and dementia; and were taking more medication classes, have a higher Charlson comorbidity index, and be hospitalized or in a skilled nursing facility in the prior year (Table I in the Data Supplement). Within 365 days after antihypertensive medication initiation, 23 315 and 30 143 beneficiaries added a class of antihypertensive medication and titrated their antihypertensive medication, respectively. A serious fall injury occurred within 15 days after adding a new class of antihypertensive medication for 0.27% (n=64) of beneficiaries and within 15 days after titration for 0.29% (n=88) of beneficiaries.

Short-Term Risk of Serious Fall Injuries Associated With Antihypertensive Medication in the Case-Crossover Study

Table 2 shows the characteristics of the 90 127 Medicare beneficiaries who had a serious fall injury between January 1, 2007, and December 31, 2012, and of the subset of 272 individuals who initiated antihypertensive medication in the 15 days before their fall. Of those initiating antihypertensive medication, 30.9%, 34.6%, and 34.6% were aged 65 to 74 years, 75 to 84 years, and ≥85 years, respectively; 28.3% were male; and 89.7% were white.

Overall, 272, 1508, and 3113 Medicare beneficiaries initiated, added a new class of antihypertensive medication, and titrated therapy, respectively, within 15 days before their serious fall injury. The short-term odds ratios (95% CI) for a serious fall injury were 1.36 (95% CI, 1.19–1.55) for initiation of antihypertensive medication, 1.16 (95% CI, 1.10–1.23) for adding a new antihypertensive medication class, and 1.13 (95% CI, 1.08–1.18) for antihypertensive medication titration (Table 3). The associations were similar when the definition of

Table 3. Short-Term Odds Ratios for a Serious Fall Injury Associated With Initiation, Adding a New Drug Class, and Antihypertensive Medication Titration

	Overall (n=90 127 Serious Fall Injuries)			Previous Hypertension Diagnosis* (n=90 127 Serious Fall Injuries)			No Recent Hospitalization† (n=60 211 Serious Fall Injuries)		
	Case Period n (%)‡	Control Periods n (%)§	OR (95% CI)	Case Period n (%)‡	Control Periods n (%)§	OR (95% CI)	Case Period n (%)‡	Control Periods n (%)§	OR (95% CI)
Initiation	272 (0.30)	1201 (0.22)	1.36 (1.19–1.55)	159 (0.18)	701 (0.13)	1.36 (1.15–1.62)	146 (0.24)	635 (0.18)	1.38 (1.15–1.65)
Addition of new class	1508 (1.67)	7820 (1.45)	1.16 (1.10–1.23)	1276 (1.42)	6664 (1.23)	1.15 (1.09–1.23)	687 (1.14)	3450 (0.95)	1.20 (1.10–1.30)
Titration	3113 (3.45)	16714 (3.09)	1.13 (1.08–1.18)	2696 (2.99)	14 542 (2.69)	1.12 (1.08–1.17)	1432 (2.38)	7662 (2.12)	1.13 (1.07–1.20)

Initiation, adding a new drug class, or antihypertensive medication titration during the case period (within 15 days before fall) were compared with the initiation of antihypertensive medication during 6 control periods (30–44, 60–74, 90–104, 120–134, 150–164, and 180–194 days before the fall).

*For the previous hypertension diagnosis, definitions of initiation, addition of a new antihypertensive medication class, and antihypertensive medication titration additionally required having 1 or more diagnoses of hypertension (*International Classification of Diseases*, Ninth Revision diagnoses of 401.xx) in the 365 days before the case or control period.

†Beneficiaries who were hospitalized within 365 days before their serious fall injury were excluded.

‡Calculated as 100 times (number of serious fall injuries in case period divided by total number of serious fall injuries).

§Calculated as 100 times (total number of serious fall injuries across the control periods divided by the product of 6 control periods times total number of serious fall injuries)

antihypertensive medication initiation, addition, and titration required 1 or more diagnoses of hypertension and when the population was restricted to Medicare beneficiaries without a recent hospitalization. The associations were similar using 1 control period (Table II in the Data Supplement). Among Medicare beneficiaries with a serious fall injury within 15 days after antihypertensive medication initiation, addition of new class, and titration, 14.0%, 15.6%, and 14.6%, respectively, died within 90 days after the fall.

Antihypertensive Medication Class Initiated in Case Versus Control Periods

Initiation of diuretics, particularly loop diuretics, was more common in the 15-day case period compared with the control periods (Table III in the Data Supplement). Initiation with other classes of antihypertensive medication was similar in the case and control periods. The percentage of beneficiaries who simultaneously initiated >1 antihypertensive class was higher in the case period (20.2%) compared with the control periods (17.4%). These results were similar when the definition of antihypertensive medication initiation required 1 or more diagnoses of hypertension and when the population was restricted to Medicare beneficiaries without a recent hospitalization

Subgroup Analyses

The association between antihypertensive medication initiation and serious fall injuries did not vary by subgroup (Table IV in the Data Supplement). The short-term odds ratio for a serious fall injury associated with the addition of a new class of antihypertensive medication was stronger for Medicare beneficiaries without a history of diabetes mellitus, without heart failure, and who were taking fewer nonantihypertensive medications (Table V in the Data Supplement). The short-term odds ratio for a serious fall injury associated with the titration of antihypertensive medication was stronger for older Medicare beneficiaries, those without a history of heart failure, and

those without chronic kidney disease (Table VI in the Data Supplement). The associations of initiation and addition of antihypertensive medication with serious fall injuries did not vary by medication class or the number of classes initiated (Table VII in the Data Supplement) or added (Table VIII in the Data Supplement).

Long-Term Risk of Serious Fall Injuries

No association was present between initiating antihypertensive medications, and, separately, adding a new class of antihypertensive medication in the 30 to 44 days, 60 to 74 days, or 90 to 104 days before a fall, and the risk for a subsequent fall injury (Table 4). The odds ratio for a serious fall injury associated with the titration of antihypertensive medication within 30 to 44 days, 60 to 74 days, and 90 to 104 days before the fall was 1.04 (95% CI, 1.00–1.09), 1.05 (95% CI, 1.00–1.09), and 1.04 (95% CI, 1.00–1.09), respectively. The associations were similar in analyses using 1 instead of 6 control periods (Table IX in the Data Supplement).

Discussion

Falls risk among elderly individuals is a major public health concern.³⁰ Falls are often attributed to the interaction of long-term predisposing conditions and short-term precipitating factors.^{27,31} The high rate of falls and risk for adverse outcomes after a fall has generated an increasing recognition of the need to identify precipitating factors for falls in older adults.¹⁴ In the current study, the odds for a serious fall injury were increased in the 15 days after antihypertensive medication initiation and intensification. An increased risk for a serious fall injury was no longer present >15 days after either initiation or adding a new class and was attenuated >15 days after titration of antihypertensive medication.

Previous studies of the short-term risks after antihypertensive medication initiation have focused on fractures as an outcome rather than the risk of falls or injuries related to falls.^{4,5,12,32} For example, Butt et al⁵ showed that hip fracture risk was

Table 4. Short-Term and Long-Term Odds Ratios for a Serious Fall Injury Associated With Initiation, Addition of New Class, and Titration of Antihypertensive Medication

	Overall (n=90 127 Serious Fall Injuries)				Previous Hypertension Diagnosis* (n=90 127 Serious Fall Injuries)			No Recent Hospitalization† (n=60 211 Serious Fall Injuries)		
	Case Period (d)	Case Period n (%)‡	Control Periods n (%)§	OR (95% CI)	Case Period n (%)‡	Control Periods n (%)§	OR (95% CI)	Case Period n (%)‡	Control Periods n (%)§	OR (95% CI)
Initiation										
	0–14	272 (0.30)	1201 (0.22)	1.36 (1.19, 1.55)	159 (0.18)	701 (0.13)	1.36 (1.15, 1.62)	146 (0.24)	635 (0.18)	1.38 (1.15, 1.65)
	30–44¶	201 (0.22)	1000 (0.22)	1.01 (0.86, 1.17)	133 (0.15)	568 (0.13)	1.17 (0.97, 1.41)	100 (0.17)	535 (0.18)	0.93 (0.75, 1.16)
	60–74#	195 (0.22)	805 (0.22)	0.97 (0.83, 1.13)	116 (0.13)	452 (0.13)	1.03 (0.84, 1.26)	111 (0.18)	424 (0.18)	1.05 (0.85, 1.29)
	90–104**	201 (0.22)	604 (0.22)	1.00 (0.85, 1.17)	116 (0.13)	336 (0.12)	1.04 (0.84, 1.28)	102 (0.17)	322 (0.18)	0.95 (0.76, 1.19)
Addition of new class										
	0–14	1508 (1.67)	7820 (1.45)	1.16 (1.10–1.23)	1276 (1.42)	6664 (1.23)	1.15 (1.09–1.23)	687 (1.14)	3450 (0.95)	1.20 (1.10–1.30)
	30–44¶	1361 (1.51)	6459 (1.43)	1.05 (0.99–1.12)	1160 (1.29)	5504 (1.22)	1.06 (0.99–1.13)	577 (0.96)	2873 (0.95)	1.00 (0.92–1.1)
	60–74#	1346 (1.49)	5113 (1.42)	1.05 (0.99–1.12)	1146 (1.27)	4358 (1.21)	1.05 (0.99–1.12)	595 (0.99)	2278 (0.95)	1.05 (0.95–1.15)
	90–104**	1290 (1.43)	3823 (1.41)	1.01 (0.95–1.08)	1105 (1.23)	3253 (1.20)	1.02 (0.95–1.09)	567 (0.94)	1711 (0.95)	0.99 (0.90–1.09)
Titration										
	0–14	3113 (3.45)	16 714 (3.09)	1.13 (1.08–1.18)	2696 (2.99)	14 542 (2.69)	1.12 (1.08–1.17)	1432 (2.38)	7662 (2.12)	1.13 (1.07–1.20)
	30–44¶	2874 (3.19)	13 840 (3.07)	1.04 (1.00–1.09)	2510 (2.78)	12 032 (2.67)	1.05 (1.00–1.10)	1275 (2.12)	6387 (2.12)	1.00 (0.94–1.06)
	60–74#	2865 (3.18)	10 975 (3.04)	1.05 (1.00–1.09)	2511 (2.79)	9521 (2.64)	1.06 (1.01–1.11)	1302 (2.16)	5085 (2.11)	1.03 (0.96–1.09)
	90–104**	2820 (3.13)	8155 (3.02)	1.04 (1.00–1.09)	2434 (2.70)	7087 (2.62)	1.03 (0.98–1.08)	1280 (2.13)	3805 (2.11)	1.01 (0.95–1.08)

*For the previous hypertension diagnosis, definitions of initiation, addition of a new antihypertensive medication class, and antihypertensive medication titration additionally required having 1 or more diagnoses of hypertension (*International Classification of Diseases*, Ninth Revision diagnoses of 401.xx) in the 365 days before the case or control period.

†Beneficiaries who were hospitalized within 365 days before their serious fall injury were excluded.

‡Calculated as 100 times (number of serious fall injuries in case period divided by total number of serious fall injuries).

§Calculated as 100 times (total number of serious fall injuries across the control periods divided by the product of number of control periods times total number of serious fall injuries).

||Six control periods: 30–44, 60–74, 90–104, 120–134, 150–164, and 180–194 d before the fall.

¶Five control periods: 60–74, 90–104, 120–134, 150–164, and 180–194 d before the fall.

#Four control periods: 90–104, 120–134, 150–164, and 180–194 d before the fall.

**Three control periods: 120–134, 150–164, and 180–194 d before the fall.

increased in the 45 days after antihypertensive medication initiation among Ontario residents who were ≥66 years. Initiation of angiotensin-converting enzyme inhibitors and β-blockers was each significantly associated with an increased risk of hip fractures, whereas thiazide diuretics, angiotensin receptor blockers, and calcium channel blockers were not. In the current study, an increased odds ratio for a serious fall injury was present when antihypertensive medication was initiated in a 15-day period before the fall but not beyond 15 days. This association did not vary by the class of antihypertensive medication initiated.

Scarce data are available on the association between antihypertensive medication intensification and the risk of a serious fall injury. In a substudy of 3099 middle age and older participants with diabetes mellitus enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Margolis et al¹¹ did not find an increased risk for self-reported falls or nonspine fractures between participants randomized to a systolic pressure of <120 mmHg versus systolic pressure of <140 mmHg. It is unclear whether these results are applicable for older adults who undergo antihypertensive medication intensification because the ACCORD substudy participants were relatively young (mean age 62 years old) and

the outcomes were ascertained years after reductions in blood pressure had occurred in the intensive treatment arm. In the current study, there was no long-term increased risk for serious falls injuries associated with antihypertensive medication use, a finding that is consistent with the findings from ACCORD.¹¹

The Systolic Blood Pressure Intervention Trial (SPRINT) recently demonstrated that a systolic blood pressure target goal of 120 mmHg (intensive treatment) versus 140 mmHg (conventional treatment) was associated with a lower risk of cardiovascular disease events and mortality in adults at least 50 years of age with a systolic blood pressure of 130 to 180 mmHg and high cardiovascular risk but without diabetes mellitus or a previous stroke.³ The intensive versus conventional treatment goal was associated with a higher risk of hypotension, syncope, electrolyte abnormalities, but not injurious falls, defined as falls that resulted in evaluation in an emergency department or hospitalization. However, when adverse events were classified as possibly or definitely related to intensive treatment, the risk of injurious falls was higher in the intensive versus conventional treatment arm (0.8% versus 0.5%; *P*=0.05). The results from the current study indicating a short-term increased risk of serious fall injuries after antihypertensive medication

intensification but no increased risk with long-term antihypertensive medication use are consistent with the findings in SPRINT. It was reported that 7.6% or 16.8 million of US adults meet the SPRINT eligibility criteria.³³ Therefore, many older US adults may have their antihypertensive medication intensified to reach a lower systolic blood pressure target and be susceptible to a short-term increased risk of serious fall injuries.

Some, but not all, studies have reported that antihypertensive medication use in older adults is associated with an increased risk for falls or fall injuries.^{4-7,11,12} Tinetti et al⁶ conducted a retrospective cohort study and found that in clinical practice, Medicare beneficiaries >70 years of age who were taking antihypertensive medication had a higher risk of a serious fall injury than their counterparts not taking antihypertensive medication. Using a case-crossover study design, which minimizes confounding by having each individual serve as his/her own control, we have extended the results of Tinetti et al⁶ to demonstrate that antihypertensive medication initiation and intensification may be associated with a short-term increased risk of serious fall injuries in older adults.

Using a retrospective cohort study design, we also showed that the risk of a serious fall injury was low within 15 days after initiating antihypertensive medication, adding a new class, and titrating antihypertensive medication. However, the risk for a fall after antihypertensive initiation and intensification is likely to be substantially higher, as serious fall injuries represent only 10% of all falls experienced by older adults.^{27,34} Serious fall injuries, including fractures, brain injuries, and dislocations, are the most adverse consequences of falls in older adults. Nonetheless, falls that do not result in a serious injury are also clinically important as they are associated with functional decline and nursing home placement in older adults.^{35,36}

There are several potential mechanisms for the short-term increased risk of serious falls associated with antihypertensive medication initiation and intensification. Older adults are at increased risk for postural hypotension,^{37,38} which may result in neurological effects and consequently balance and gait impairment. In addition, antihypertensive medication-induced electrolyte disturbances may cause neurological and physical side effects, which may make older adults more susceptible to falls.^{9,10,39,40} Multicomponent interventions that include multiple risk factor assessment, physical therapy, and exercise are effective in falls prevention.^{14,41} These strategies could be adopted by clinicians in the short-term to prevent falls and fall-related injuries when antihypertensive medication is initiated or intensified in their older patients.

There are several strengths of the current study. Given the longitudinal nature of Medicare claims, we were able to study serious injuries after antihypertensive medication initiation and intensification. Another strength of the study is that Medicare provides data that are highly generalizable to older adults in the United States. Some limitations must be noted. The generalizability to younger adults may be limited. Also, as with all claims-based analyses, the results depend on the accuracy of coding of disease states and pharmacy fills. Because blood pressure data are not available in Medicare claims, we could not determine whether the associations we report can be explained by changes in blood pressure levels. Because there was a lack of information on falls that did not result in a serious

injury, we could not determine whether antihypertensive medication initiation or intensification was associated with less serious falls. Another potential limitation is the assumption that clinical characteristics were stable over time in the case-crossover study. Given that the duration between the control periods and the case period was relatively short (195 days or less), it is likely that substantial changes in clinical characteristics did not occur. It was not possible to determine the exact timing between antihypertensive medication initiation and intensification and the occurrence of the serious fall injury using Medicare claims. However, the inability to pinpoint the timing of the outcome and the appropriate time window for the exposure will likely bias results toward the null.^{42,43} Therefore, if the exact time course were known, the associations of antihypertensive medication initiation and intensification with the risk of serious fall injuries would be even stronger. Finally, although the case-crossover study demonstrated that antihypertensive medication initiation and intensification are associated with an increased risk of serious fall injuries, caution is warranted when concluding the results indicate causality.

In conclusion, the results of the current study indicate that the initiation and intensification of antihypertensive medication are associated with a short-term increased risk of a serious fall injury in older adults. However, the short-term risk of a serious fall injury is low, and there does not seem to be a long-term increased risk for serious fall injuries associated with antihypertensive medication. The short-term risk of serious fall injuries, as well as approaches, for reducing this risk should be discussed with older patients when initiating or intensifying antihypertensive medication.

Sources of Funding

This work was supported by the National Institutes of Health (K24-HL125704) from the National Heart, Lung, and Blood Institute, Bethesda, MD.

Disclosures

Drs Muntner and Levitan have received institutional grants from Amgen Inc. unrelated to the topic of the current article. The other authors report no conflicts.

References

1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311:507-520. doi: 10.1001/jama.2013.284427.
2. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens*. 2014;32:3-15. doi: 10.1097/HJH.0000000000000065.
3. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103-2116. doi: 10.1056/NEJMoa1511939.

4. Berry SD, Zhu Y, Choi H, Kiel DP, Zhang Y. Diuretic initiation and the acute risk of hip fracture. *Osteoporos Int*. 2013;24:689–695. doi: 10.1007/s00198-012-2053-3.
5. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. *Arch Intern Med*. 2012;172:1739–1744. doi: 10.1001/2013.jamainternmed.469.
6. Tinetti ME, Han L, Lee DS, McAvay GJ, Peduzzi P, Gross CP, Zhou B, Lin H. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. *JAMA Intern Med*. 2014;174:588–595. doi: 10.1001/jamainternmed.2013.14764.
7. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. *Arch Intern Med*. 2009;169:1952–1960. doi: 10.1001/archinternmed.2009.357.
8. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. *J Am Coll Cardiol*. 2011;57:2037–2114. doi: 10.1016/j.jacc.2011.01.008.
9. Ahuja TS, Freeman D Jr, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. *Am J Nephrol*. 2000;20:268–272. doi: 13599.
10. Officers A, Coordinators of the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). *JAMA*. 2002;288:2981–2997.
11. Margolis KL, Palermo L, Vittinghoff E, Evans GW, Atkinson HH, Hamilton BP, Josse RG, O'Connor PJ, Simmons DL, Tiktin M, Schwartz AV. Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. *J Gen Intern Med*. 2014;29:1599–1606. doi: 10.1007/s11606-014-2961-3.
12. Peters R, Beckett N, Burch L, de Vernejoul MC, Liu L, Duggan J, Swift C, Gil-Extremera B, Fletcher A, Bulpitt C. The effect of treatment based on a diuretic (indapamide) +/- ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). *Age Ageing*. 2010;39:609–616. doi: 10.1093/ageing/afq071.
13. Kent ST, Shimbo D, Huang L, Diaz KM, Viera AJ, Kilgore M, Oparil S, Muntner P. Rates, amounts, and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries. *J Am Soc Hypertens*. 2014;8:898–908. doi: 10.1016/j.jash.2014.09.020.
14. AGS/BGS Clinical Practice Guideline: Prevention of Falls in Older Persons. 2010. <http://www.medicare.com/FALLS/content/toc.htm>. Accessed March 15, 2016.
15. Kent ST, Shimbo D, Huang L, Diaz KM, Kilgore ML, Oparil S, Muntner P. Antihypertensive medication classes used among Medicare beneficiaries initiating treatment in 2007–2010. *PLoS One*. 2014;9:e105888. doi: 10.1371/journal.pone.0105888.
16. Link MS, Luttmann-Gibson H, Schwartz J, Mittleman MA, Wessler B, Gold DR, Dockery DW, Laden F. Acute exposure to air pollution triggers atrial fibrillation. *J Am Coll Cardiol*. 2013;62:816–825. doi: 10.1016/j.jacc.2013.05.043.
17. Mostofsky E, Maclure M, Sherwood JB, Tofler GH, Muller JE, Mittleman MA. Risk of acute myocardial infarction after the death of a significant person in one's life: the Determinants of Myocardial Infarction Onset Study. *Circulation*. 2012;125:491–496. doi: 10.1161/CIRCULATIONAHA.111.061770.
18. Mostofsky E, van der Bom JG, Mukamal KJ, Maclure M, Tofler GH, Muller JE, Mittleman MA. Risk of myocardial infarction immediately after alcohol consumption. *Epidemiology*. 2015;26:143–150. doi: 10.1097/EDE.0000000000000227.
19. Chronic condition data warehouse: chronic condition categories. http://www.ccwdata.org/cs/groups/public/documents/document/ccw_condition-categories2011.pdf. Accessed March 15, 2016.
20. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. *Ann Epidemiol*. 1995;5:278–285. doi: 10.1016/1047-2797(94)00093-9.
21. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. *Diabetes Care*. 2004;27(suppl 2):B10–B21. doi: 10.2337/diacare.27.suppl_2.B10.
22. Muntner P, Gutiérrez OM, Zhao H, Fox CS, Wright NC, Curtis JR, McClellan W, Wang H, Kilgore M, Warnock DG, Bowling CB. Validation study of Medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Am J Kidney Dis*. 2015;65:249–258. doi: 10.1053/j.ajkd.2014.07.012.
23. Sun BC, Derose SF, Liang LJ, Gabayan GZ, Hoffman JR, Moore AA, Mower WR, Mangione CM. Predictors of 30-day serious events in older patients with syncope. *Ann Emerg Med*. 2009;54:769–778.e1. doi: 10.1016/j.annemergmed.2009.07.027.
24. Taylor DH Jr, Østbye T, Langa KM, Weir D, Plassman BL. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. *J Alzheimers Dis*. 2009;17:807–815. doi: 10.3233/JAD-2009-1099.
25. Yun H, Delzell E, Ensrud KE, Kilgore ML, Becker D, Morrissey MA, Curtis JR. Predicting hip and major osteoporotic fractures using administrative data. *Arch Intern Med*. 2010;170:1940–1942. doi: 10.1001/archinternmed.2010.410.
26. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. *J Clin Epidemiol*. 1993;46:1075–1089; discussion 1081.
27. Tinetti ME, Kumar C. The patient who falls: "It's always a trade-off." *JAMA*. 2010;303:258–266. doi: 10.1001/jama.2009.2024.
28. Tinetti ME. Clinical practice. Preventing falls in elderly persons. *N Engl J Med*. 2003;348:42–49. doi: 10.1056/NEJMcp020719.
29. Gribbin J, Hubbard R, Gladman J, Smith C, Lewis S. Risk of falls associated with antihypertensive medication: self-controlled case series. *Pharmacoepidemiol Drug Saf*. 2011;20:879–884. doi: 10.1002/pds.2176.
30. Phelan EA, Mahoney JE, Voit JC, Stevens JA. Assessment and management of fall risk in primary care settings. *Med Clin North Am*. 2015;99:281–293. doi: 10.1016/j.mcna.2014.11.004.
31. Tinetti ME, Inouye SK, Gill TM, Doucette JT. Shared risk factors for falls, incontinence, and functional dependence. Unifying the approach to geriatric syndromes. *JAMA*. 1995;273:1348–1353. doi: 10.1001/jama.1995.03520410042024.
32. Solomon DH, Mogun H, Garneau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. *J Bone Miner Res*. 2011;26:1561–1567. doi: 10.1002/jbmr.356.
33. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT Results to the U.S. Adult Population. *J Am Coll Cardiol*. 2016;67:463–472. doi: 10.1016/j.jacc.2015.10.037.
34. Tinetti ME, Doucette J, Claus E, Marottoli R. Risk factors for serious injury during falls by older persons in the community. *J Am Geriatr Soc*. 1995;43:1214–1221.
35. Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. *N Engl J Med*. 1997;337:1279–1284. doi: 10.1056/NEJM199710303371806.
36. Tinetti ME, Williams CS. The effect of falls and fall injuries on functioning in community-dwelling older persons. *J Gerontol A Biol Sci Med Sci*. 1998;53:M112–M119.
37. Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and treatment. *Am J Med*. 2007;120:841–847. doi: 10.1016/j.amjmed.2007.02.023.
38. Masuo K, Mikami H, Ogihara T, Tuck ML. Changes in frequency of orthostatic hypotension in elderly hypertensive patients under medications. *Am J Hypertens*. 1996;9:263–268. doi: 10.1016/0895-7061(95)00348-7.
39. Itescu S, Haskell LP, Tannenber AM. Thiazide-induced clinically significant hypophosphatemia. *Clin Nephrol*. 1987;27:161–162.
40. Swales JD. Magnesium deficiency and diuretics. *BMJ*. 1982;285:1377–1378. doi: 10.1136/bmj.285.6352.1377.
41. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE. Interventions for preventing falls in older people living in the community. *Cochrane Database Syst Rev*. 2012;9:CD007146. doi: 10.1002/14651858.CD007146.pub3.
42. Lokken RP, Wellenius GA, Coull BA, Burger MR, Schlaug G, Suh HH, Mittleman MA. Air pollution and risk of stroke: underestimation of effect due to misclassification of time of event onset. *Epidemiology*. 2009;20:137–142.
43. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. *Am J Epidemiol*. 1991;133:144–153.

Short-Term Risk of Serious Fall Injuries in Older Adults Initiating and Intensifying Treatment With Antihypertensive Medication

Daichi Shimbo, C. Barrett Bowling, Emily B. Levitan, Luqin Deng, John J. Sim, Lei Huang, Kristi Reynolds and Paul Muntner

Circ Cardiovasc Qual Outcomes. 2016;9:222-229; originally published online May 10, 2016;
doi: 10.1161/CIRCOUTCOMES.115.002524

Circulation: Cardiovascular Quality and Outcomes is published by the American Heart Association, 7272
Greenville Avenue, Dallas, TX 75231

Copyright © 2016 American Heart Association, Inc. All rights reserved.

Print ISSN: 1941-7705. Online ISSN: 1941-7713

The online version of this article, along with updated information and services, is located on the
World Wide Web at:

<http://circoutcomes.ahajournals.org/content/9/3/222>

Data Supplement (unedited) at:

<http://circoutcomes.ahajournals.org/content/suppl/2016/05/10/CIRCOUTCOMES.115.002524.DC1>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation: Cardiovascular Quality and Outcomes* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:

<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation: Cardiovascular Quality and Outcomes* is online at:

<http://circoutcomes.ahajournals.org//subscriptions/>

SUPPLEMENTAL MATERIAL

Supplemental Table 1. Characteristics of Medicare beneficiaries in the retrospective cohort study who had and did not have a serious fall injury within 15 days following initiation of antihypertensive medication

Characteristic	With serious fall injury (N=186)	Without serious fall injury (N=65,024)
Age at initiation of antihypertensive medication		
<75 years	56 (30.1%)	31,057 (47.8%)
75 –84years	72 (38.7%)	23,234 (35.7%)
≥ 85 years	58 (31.2%)	10,733 (16.5%)
Male sex	50 (26.9%)	25,708 (39.5%)
Race/ethnicity		
White	158 (84.9%)	53,578 (82.4%)
African American	15 (8.1%)	5,732 (8.8%)
Other	13 (7.0%)	5,714 (8.8%)
Region		
Northeast	30 (16.1%)	12,091 (18.6%)
Midwest	55 (29.6%)	14,436 (22.2%)
South	70 (37.6%)	26,759 (41.2%)
West	31 (16.7%)	11,738 (18.1%)
Calendar month of fall		
January	15 (8.1%)	6,704 (10.3%)
February	17 (9.1%)	5,487 (8.4%)
March	13 (7.0%)	5,835 (9.0%)
April	12 (6.5%)	5,391 (8.3%)
May	9 (4.8%)	5,383 (8.3%)
June	13 (7.0%)	5,457 (8.4%)
July	20 (10.8%)	5,139 (7.9%)
August	22 (11.8%)	5,168 (7.9%)
September	11 (5.9%)	4,900 (7.5%)
October	24 (12.9%)	5,257 (8.1%)
November	17 (9.1%)	5,097 (7.8%)
December	13 (7.0%)	5,206 (8.0%)
History of Diabetes	34 (18.3%)	14,605 (22.5%)
History of CHD	47 (25.3%)	11,455 (17.6%)
History of heart failure	28 (15.1%)	4,579 (7.0%)
History of stroke	12 (6.5%)	1,813 (2.8%)
History of CKD	27 (14.5%)	7,945 (12.2%)
History of syncope	29 (15.6%)	5,145 (7.9%)
History of osteoporosis	66 (35.5%)	10,157 (15.6%)
History of depression	59 (31.7%)	8,332 (12.8%)
History of dementia	64 (34.4%)	8,587 (13.2%)
Number of medication classes		
0-5	87 (46.8%)	36,716 (56.5%)
6-10	52 (28.0%)	17,791 (27.4%)
>10	47 (25.3%)	10,517 (16.2%)

Charlson comorbidity index		
0	104 (55.9%)	50,390 (77.5%)
1-3	46 (24.7%)	8,997 (13.8%)
≥ 4	36 (19.4%)	5,637 (8.7%)
Any hospitalization in the prior year	105 (56.5%)	19,482 (30.0%)
Skilled nursing facility stay in the prior year	54 (29.0%)	7,302 (11.2%)

Data are expressed as number (percentage).

Supplemental Table 2. Short-term odds ratios for a serious fall injury associated with initiation, adding a new drug class or antihypertensive medication titration using one* instead of six control periods

	Overall	Prior hypertension diagnosis	No recent hospitalization
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Initiation	1.39 (1.16, 1.68)	1.37 (1.08, 1.74)	1.32 (1.03, 1.68)
Addition of new class	1.12 (1.04, 1.21)	1.12 (1.03, 1.21)	1.16 (1.04, 1.29)
Titration	1.09 (1.04, 1.15)	1.08 (1.02, 1.14)	1.11 (1.03, 1.20)

Numbers in the table are odds ratio (95% confidence interval)

*60-74 days prior to the fall.

Supplemental Table 3. Number and percentage of Medicare beneficiaries initiating antihypertensive medication during the case period (0-14 days prior to fall) and control periods*

Antihypertensive medication class	Overall		With hypertension diagnosis		Without a recent hospitalization	
	Case (n=272)	Control (n=1,201)	Case (n=159)	Control (n=701)	Case (n=146)	Control (n=635)
ACE-inhibitors or angiotensin receptor blockers	84 (30.9%)	374 (31.1%)	55 (34.6%)	242 (34.5%)	51 (34.9%)	221 (34.8%)
Beta blockers	74 (27.2%)	351 (29.2%)	45 (28.3%)	217 (31.0%)	20 (13.7%)	151 (23.8%)
All diuretics	116 (42.6%)	474 (39.5%)	65 (40.9%)	250 (35.7%)	67 (45.9%)	245 (38.6%)
Thiazide-type	33 (12.1%)	165 (13.7%)	19 (11.9%)	92 (13.1%)	19 (13.0%)	107 (16.9%)
Loop	78 (28.7%)	276 (23.0%)	41 (25.8%)	144 (20.5%)	44 (30.1%)	111 (17.5%)
Potassium-sparing	Non-applicable	38 (3.2%)	Non-applicable	17 (2.4%)	Non-applicable	27 (4.3%)
Calcium channel blockers	40 (14.7%)	192 (16.0%)	29 (18.2%)	141 (20.1%)	14 (9.6%)	80 (12.6%)
Others*	21 (7.7%)	57 (4.7%)	13 (8.2%)	29 (4.1%)	12 (8.2%)	31 (4.9%)
Initiating >1 antihypertensive class	55 (20.2%)	209 (17.4%)	41 (25.8%)	147 (21.0%)	19 (13.0%)	80 (12.6%)

Numbers and percentages in the column heading are those who initiated an antihypertensive medication during the case and control periods.

Non-applicable = cell sizes < 11 are suppressed as per Medicare data regulations.

This table includes all antihypertensive medications that are filled during the case and control periods.

*Six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

ACE = angiotensin-converting enzyme

Supplemental Table 4. Short-term odds ratios for a serious fall injury associated with initiation of antihypertensive medication by subgroup

Characteristic	N initiating in case period (N=272)	Odds ratio (95% CI)	p-value for homogeneity
Age on fall date			0.233
<75 years	84 (30.9%)	1.58 (1.25, 2.02)	
75 – 84 years	94 (34.6%)	1.19 (0.96, 1.49)	
≥ 85 years	94 (34.6%)	1.38 (1.10, 1.72)	
Male	77 (28.3%)	1.40 (1.09, 1.79)	0.803
Female	195 (71.7%)	1.34 (1.15, 1.57)	
White	244 (89.7%)	1.37 (1.19, 1.57)	0.799
Non-white	28 (10.3%)	1.24 (0.67, 2.31)	
Region			0.557
Northeast	47 (17.3%)	1.35 (0.98, 1.85)	
Midwest	69 (25.4%)	1.42 (1.09, 1.84)	
South	110 (40.4%)	1.46 (1.18, 1.79)	
West	46 (16.9%)	1.12 (0.82, 1.53)	
Calendar month of fall			0.591
January	22 (8.1%)	1.28 (0.81, 2.03)	
February	23 (8.5%)	2.19 (1.36, 3.53)	
March	15 (5.5%)	0.97 (0.56, 1.67)	
April	24 (8.8%)	1.52 (0.97, 2.37)	
May	19 (7.0%)	1.27 (0.77, 2.08)	
June	21 (7.7%)	1.30 (0.81, 2.08)	
July	27 (8.5%)	1.62 (1.06, 2.48)	
August	21 (7.7%)	1.08 (0.68, 1.71)	
September	23 (8.5%)	1.24 (0.79, 1.95)	
October	23 (8.5%)	1.09 (0.70, 1.69)	
November	24 (8.8%)	1.53 (0.98, 2.40)	
December	30 (11.0%)	1.62 (1.08, 2.43)	
No Diabetes	218 (80.1%)	1.34 (1.16, 1.55)	0.671
Diabetes	54 (19.9%)	1.44 (1.07, 1.94)	
No CHD	206 (75.7%)	1.35 (1.16, 1.57)	0.898
CHD	66 (24.3%)	1.38 (1.06, 1.80)	
No heart failure	236 (86.8%)	1.39 (1.21, 1.60)	0.421
Heart failure	36 (13.2%)	1.19 (0.83, 1.70)	
No stroke	260 (95.6%)	1.37 (1.20, 1.57)	0.472
Stroke	12 (4.4%)	1.09 (0.59, 2.02)	
No CKD	225 (82.7%)	1.37 (1.19, 1.59)	0.712
CKD	47 (17.3%)	1.29 (0.94, 1.76)	
No syncope	239 (87.4%)	1.39 (1.21, 1.60)	0.402
Syncope	33 (12.1%)	1.17 (0.81, 1.70)	
No osteoporosis	211 (77.6%)	1.39 (1.20, 1.62)	0.529
Osteoporosis	61 (22.4%)	1.26 (0.95, 1.66)	
No depression	202 (74.3%)	1.35 (1.16, 1.57)	0.885
Depression	70 (25.7%)	1.38 (1.07, 1.79)	

No dementia	204 (75.0%)	1.42 (1.22, 1.65)	0.308
dementia	68 (25.0%)	1.21 (0.93, 1.57)	
Number of medication classes			0.173
0– 5	75 (27.6%)	1.69 (1.30, 2.18)	
6 – 10	90 (33.1%)	1.24 (0.99, 1.55)	
>10	107 (39.3%)	1.29 (1.05, 1.59)	
Charlson comorbidity index			0.659
0	167 (61.4%)	1.34 (1.14, 1.59)	
1-3	61 (22.4%)	1.51 (1.14, 1.99)	
≥ 4	44 (16.2%)	1.24 (0.90, 1.71)	
No hospitalization in the prior year	146 (53.7%)	1.38 (1.15, 1.65)	0.810
Hospitalization in the prior year	126 (46.3%)	1.34 (1.10, 1.62)	
No skills nursing facility in the prior year	218 (80.1%)	1.34 (1.16, 1.55)	0.671
Skills nursing facility in the prior year	54 (19.9%)	1.44 (1.07, 1.94)	

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

CHD = coronary heart disease, CKD = chronic kidney disease

Supplemental Table 5. Short-term odds ratios for a serious fall injury associated with addition of new class by subgroup

Characteristic	N adding new class in case period (N=1,508)	Odds ratio (95% CI)	p-value for homogeneity
Age on fall date			0.076
<75 years	370 (24.5%)	1.15 (1.02, 1.28)	
85 – 84 years	591 (39.2%)	1.09 (1.00, 1.19)	
≥ 85 years	547 (36.3%)	1.26 (1.15, 1.39)	
Male	1,145 (75.9%)	1.17 (1.04, 1.31)	0.931
Female	363 (24.1%)	1.16 (1.09, 1.24)	
White	1,314 (87.1%)	1.16 (1.10, 1.23)	0.917
Non-white	194 (22.9%)	1.14 (0.90, 1.43)	
Region			0.765
Northeast	259 (17.2%)	1.10 (0.97, 1.26)	
Midwest	368 (24.4%)	1.17 (1.05, 1.31)	
South	629 (41.7%)	1.19 (1.09, 1.30)	
West	252 (16.7%)	1.13 (0.98, 1.29)	
Calendar month of fall			0.238
January	121 (8.0%)	1.20 (0.99, 1.47)	
February	110 (7.3%)	1.27 (1.03, 1.57)	
March	110 (7.3%)	1.14 (0.93, 1.40)	
April	122 (8.1%)	1.26 (1.03, 1.54)	
May	126 (8.4%)	1.31 (1.08, 1.59)	
June	128 (8.5%)	1.25 (1.03, 1.52)	
July	138 (9.2%)	1.21 (1.00, 1.45)	
August	108 (7.2%)	0.86 (0.70, 1.05)	
September	132 (8.8%)	1.15 (0.95, 1.39)	
October	130 (8.6%)	1.06 (0.88, 1.29)	
November	132 (8.8%)	1.16 (0.96, 1.40)	
December	151 (10.0%)	1.17 (0.98, 1.40)	
No Diabetes	1,042 (69.1%)	1.21 (1.13, 1.30)	0.032
Diabetes	466 (30.9%)	1.06 (0.96, 1.17)	
No CHD	959 (63.6%)	1.20 (1.12, 1.29)	0.120
CHD	549 (36.4%)	1.10 (1.00, 1.20)	
No heart failure	1,104 (73.2%)	1.23 (1.16, 1.32)	0.001
Heart failure	404 (26.8%)	1.00 (0.90, 1.11)	
No stroke	1,433 (95.0%)	1.17 (1.11, 1.24)	0.172
Stroke	75 (5.0%)	0.98 (0.77, 1.26)	
No CKD	1,040 (69.0%)	1.20 (1.12, 1.29)	0.077
CKD	468 (31.0%)	1.08 (0.98, 1.19)	
No syncope	1,267 (84.0%)	1.17 (1.10, 1.24)	0.775
Syncope	241 (16.0%)	1.14 (0.99, 1.31)	
No osteoporosis	1,160 (77.0%)	1.15 (1.07, 1.22)	0.361
Osteoporosis	348 (23.1%)	1.22 (1.08, 1.37)	
No depression	1,129 (74.9%)	1.18 (1.11, 1.26)	0.366
Depression	379 (25.1%)	1.11 (0.99, 1.24)	

No dementia	1,156 (76.7%)	1.14 (1.07, 1.22)	0.257
dementia	352 (23.3%)	1.23 (1.10, 1.38)	
Number of medication classes			0.002
0– 5	138 (9.2%)	1.60 (1.32, 1.93)	
6 – 10	372 (24.7%)	1.20 (1.07, 1.34)	
>10	998 (66.2%)	1.11 (1.03, 1.18)	
Charlson comorbidity index			0.321
0	805 (53.4%)	1.21 (1.12, 1.30)	
1-3	308 (20.4%)	1.13 (1.00, 1.28)	
≥ 4	395 (26.2%)	1.10 (0.98, 1.22)	
No hospitalization in the prior year	687 (45.6%)	1.20 (1.10, 1.30)	0.313
Hospitalization in the prior year	821 (54.4%)	1.13 (1.05, 1.22)	
No skills nursing facility in the prior year	1,173 (77.8%)	1.15 (1.08, 1.22)	0.397
Skills nursing facility in the prior year	335 (22.2%)	1.22 (1.08, 1.37)	

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

CHD = coronary heart disease, CKD = chronic kidney disease

Supplemental Table 6. Short-term odds ratios for a serious fall injury associated with titration of antihypertensive medication by subgroup

Characteristic	N titration in case period (N=3,113)	Odds ratio (95% CI)	p-value for homogeneity
Age on fall date			0.024
<75 years	683 (21.9%)	1.05 (0.96, 1.14)	
85 – 84 years	1,219 (39.2%)	1.11 (1.04, 1.18)	
≥ 85 years	1,211 (38.9%)	1.21 (1.13, 1.29)	
Male	734 (23.6%)	1.16 (1.07, 1.26)	0.462
Female	2,379 (76.4%)	1.12 (1.07, 1.17)	
White	2,737 (87.9%)	1.14 (1.09, 1.19)	0.319
Non-white	376 (12.1%)	1.09 (0.92, 1.29)	
Region			0.108
Northeast	558 (17.9%)	1.06 (0.96, 1.16)	
Midwest	843 (27.1%)	1.22 (1.12, 1.31)	
South	1,232 (39.6%)	1.13 (1.06, 1.20)	
West	480 (15.4%)	1.08 (0.97, 1.19)	
Calendar month of fall			0.436
January	243 (7.8%)	1.10 (0.95, 1.27)	
February	248 (8.0%)	1.30 (1.13, 1.50)	
March	219 (7.0%)	1.04 (0.90, 1.21)	
April	240 (7.7%)	1.16 (1.01, 1.34)	
May	237 (7.6%)	1.14 (0.99, 1.32)	
June	258 (8.3%)	1.23 (1.07, 1.42)	
July	280 (9.0%)	1.19 (1.04, 1.36)	
August	275 (8.8%)	1.04 (0.91, 1.19)	
September	281 (9.0%)	1.19 (1.04, 1.36)	
October	278 (8.9%)	1.05 (0.92, 1.20)	
November	251 (8.1%)	1.05 (0.91, 1.21)	
December	303 (9.7%)	1.11 (0.98, 1.26)	
No Diabetes	2,035 (65.4%)	1.15 (1.09, 1.21)	0.263
Diabetes	1,078 (34.6%)	1.09 (1.02, 1.17)	
No CHD	1,884 (60.5%)	1.15 (1.10, 1.22)	0.169
CHD	1,229 (39.5%)	1.09 (1.02, 1.16)	
No heart failure	2,125 (68.3%)	1.17 (1.11, 1.23)	0.011
Heart failure	988 (31.7%)	1.05 (0.97, 1.12)	
No stroke	2,962 (95.1%)	1.14 (1.09, 1.18)	0.155
Stroke	151 (4.9%)	0.99 (0.83, 1.19)	
No CKD	2,074 (66.6%)	1.16 (1.11, 1.22)	0.047
CKD	1,039 (33.4%)	1.07 (0.99, 1.14)	
No syncope	2,645 (85.0%)	1.14 (1.09, 1.19)	0.225
Syncope	468 (15.0%)	1.06 (0.96, 1.18)	
No osteoporosis	2,393 (76.9%)	1.11 (1.06, 1.16)	0.183
Osteoporosis	720 (23.1%)	1.19 (1.09, 1.29)	
No depression	2,351 (75.5%)	1.15 (1.10, 1.21)	0.107
Depression	762 (24.5%)	1.07 (0.98, 1.16)	

No dementia	2,366 (76.0%)	1.11 (1.06, 1.16)	0.164
dementia	747 (24.0%)	1.19 (1.09, 1.29)	
Number of medication classes			0.128
0– 5	204 (6.6%)	1.31 (1.13, 1.53)	
6 – 10	698 (22.4%)	1.14 (1.05, 1.24)	
>10	2,211 (71.0%)	1.11 (1.06, 1.16)	
Charlson comorbidity index			0.703
0	1,657 (53.2%)	1.15 (1.09, 1.21)	
1-3	587 (18.9%)	1.11 (1.01, 1.22)	
≥ 4	869 (27.9%)	1.11 (1.03, 1.20)	
No hospitalization in the prior year	1,432 (46.0%)	1.13 (1.07, 1.20)	0.916
Hospitalization in the prior year	1,681 (54.0%)	1.13 (1.07, 1.19)	
No skills nursing facility in the prior year	2,427 (78.0%)	1.12 (1.07, 1.17)	0.616
Skills nursing facility in the prior year	686 (22.0%)	1.15 (1.06, 1.25)	

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

CHD = coronary heart disease, CKD = chronic kidney disease

Supplemental Table 7. Short-term odds ratios for a serious fall injury associated with initiation of antihypertensive medication by class and number of antihypertensive medication

Characteristic	N in case period (N=272)	Odds ratio (95% CI)	p-value for homogeneity
Antihypertensive medication class			0.816
ACE-inhibitors or angiotensin receptor blockers	84 (30.9%)	1.35 (1.06, 1.71)	
Beta blockers	74 (27.2%)	1.26 (0.98, 1.63)	
Calcium channel blockers	40 (14.7%)	1.25 (0.89, 1.76)	
Any diuretic	116 (42.7%)	1.47 (1.20, 1.80)	
Type of diuretic			0.334
Thiazide diuretic	33 (12.1%)	1.20 (0.83, 1.74)	
Loop diuretic	78 (28.7%)	1.70 (1.32, 2.18)	
Potassium sparing diuretic	8 (2.9%)	1.26 (0.59, 2.71)	
Number of classes			0.280
One class	217 (79.8%)	1.31 (1.13, 1.52)	
2 or more classes	55 (20.2%)	1.58 (1.17, 2.13)	

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

ACE = angiotensin-converting enzyme

Supplemental Table 8. Short-term odds ratios for a serious fall injury associated with addition of new class of antihypertensive medication by class and number of antihypertensive medication

Characteristic	N in case period (N=1,508)	Odds ratio (95% CI)	p-value for homogeneity
Antihypertensive medication class			0.994
ACE-inhibitors or angiotensin receptor blockers	379 (25.1%)	1.17 (1.05, 1.31)	
Beta blockers	273 (18.1%)	1.16 (1.02, 1.32)	
Calcium channel blockers	241 (16.0%)	1.16 (1.01, 1.33)	
Any diuretic	593 (39.3%)	1.16 (1.06, 1.27)	
Type of diuretic			0.086
Thiazide diuretic	195 (12.9%)	1.11 (0.95, 1.29)	
Loop diuretic	375 (24.9%)	1.22 (1.09, 1.37)	
Potassium sparing diuretic	27 (1.8%)	0.80 (0.53, 1.19)	
Number of classes			0.089
One class	1327 (88.0%)	1.14 (1.08, 1.21)	
2 or more classes	181 (12.0%)	1.32 (1.13, 1.55)	

This analysis used six control periods: 30-44, 60-74, 90-104, 120-134, 150-164, and 180-194 days prior to the fall.

ACE = angiotensin-converting enzyme

Supplemental Table 9. Short-term and long-term odds ratios for a serious fall injury associated with initiation, addition of new class, and titration of antihypertensive medication using one control period


	Case period	Odds ratio (95% CI)		
		Overall	Prior hypertension diagnosis	No recent hospitalization
Initiation	0-14 days*	1.39 (1.16, 1.68)	1.37 (1.08, 1.74)	1.32 (1.03, 1.68)
	30-44 days†	1.00 (0.82, 1.22)	1.15 (0.89, 1.47)	0.98 (0.74, 1.29)
	60-74 days‡	1.01 (0.82, 1.23)	1.03 (0.79, 1.33)	1.04 (0.80, 1.35)
	90-104 days§	1.01 (0.83, 1.23)	1.01 (0.78, 1.31)	0.98 (0.75, 1.29)
Addition of new class	0-14 days*	1.12 (1.04, 1.21)	1.12 (1.03, 1.21)	1.16 (1.04, 1.29)
	30-44 days†	1.06 (0.98, 1.14)	1.05 (0.97, 1.14)	1.02 (0.91, 1.14)
	60-74 days‡	1.03 (0.95, 1.11)	1.02 (0.94, 1.11)	0.97 (0.87, 1.09)
	90-104 days§	1.04 (0.96, 1.13)	1.04 (0.96, 1.14)	1.06 (0.94, 1.20)
Titration	0-14 days*	1.09 (1.04, 1.15)	1.08 (1.02, 1.14)	1.11 (1.03, 1.20)
	30-44 days†	1.02 (0.97, 1.08)	1.03 (0.98, 1.10)	1.00 (0.92, 1.08)
	60-74 days‡	1.03 (0.97, 1.09)	1.03 (0.97, 1.09)	0.97 (0.89, 1.05)
	90-104 days§	1.07 (1.01, 1.13)	1.07 (1.01, 1.14)	1.05 (0.97, 1.14)

Numbers in table are odds ratio (95% confidence interval)

Control periods:

*60-74 days prior to the fall.
†90-104 days prior to the fall.
‡120-134 days prior to the fall.
§150-164 days prior to the fall.

Supplemental Figure 1. Flow diagram for the analysis of Medicare beneficiaries in the retrospective cohort study.



*The start of the look back period is the 365 days prior to the first antihypertensive medication fill.

Supplemental Figure 2. Flow diagram for the analysis of Medicare beneficiaries in the case-crossover study

